Is there an optimal timing of autologous stem-cell transplantation for multiple myeloma in the era of novel agents?

References (11)

1. Harousseau JL. How to select among available options for the treatment of multiple myeloma. Ann Oncol 2012;23(Suppl 10):334-338
2. Harousseau JL, Moreau P. Autologous hematopoietic stem- cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-2654
3. Cavo M, Tacchetti P, Patriarca F Petrucci MT, Pantani L, Galli M, Di Raimondo F Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075-2085
4. Palumbo A, Gay F Falco P, Crippa C, Montefusco V, Patriarca F Rossini F Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800-807
5. Blanes M, de la Rubia J. Role of autologous bone marrow transplant in multiple myeloma. Curr Opin Oncol 2012;24:733-741
6. Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP 3rd. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13:183-196
7. Lonial S, Miguel JF Induction therapy for newly diagnosed multiple myeloma. J Natl Compr Canc Netw 2013;11:19- 28
8. Moreau P, Rajkumar SV. Should all eligible patients with multiple myeloma receive autologous stem-cell transplant as part of initial treatment? Leuk Res 2012;36:677-681
9. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012;87:78-88
10. Kumar SK, Lacy MQ, Dispenzieri A, Buadi FK, Hayman SR, Dingli D, Gay F Sinha S, Leung N, Hogan W, Rajkumar SV, Gertz MA. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2012;118:1585-1592
11. Boccadoro M, Cavallo F Nagler A, Ben Yehuda D